1. Construction of a neoadjuvant chemoimmuntherapy cohort of resectable stage 2-3 lung cancer patients and acquisition of clinical-pathological-radiological data.
2. Plasma from individual patient will be collected at preneoadjuvant and postneoadjuvant stages and ctDNA analysis will be performed.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven clinical stage II-III lung cancer patients
No driver mutations (EGFR mutation and ALK alteration)
Whole body performance (ECOG) 0-1
Those over 19 years of age
Subject who submitted Informed consent form
You may not be if
Under 19 years of age
If there is a history of causing infection or other serious medical problems that impair the patient's function and make it difficult to comply with the study protocol.
Patients for whom the investigator determines that the patient should not participate in the clinical trial because the patient is judged to be unable to comply with the clinical trial procedures and requirements (a person lacking medical capacity)
Other patients (pregnant women, etc.) determined by the clinical trial director to be unsuitable for this clinical trial.
Clareo Health | Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Small Cell Lung Cancer
